Clinical Trial of YH14618 in Patients With Degenerative Disc Disease

Inclusion Criteria: * Patients diagnosed as one or two symptomatic early lumbar (L1/L2 \~ L5/S1) degenerative disc disease defined as Pfirrmann grade 2 to 4 using MRI performed within 4 weeks prior to randomization. * Patients have suffered from persistent low back pain with at least 3-month conservative therapy. * Patients have low back pain measured by VAS≥4cm and mODI≥30% at screening and randomization visit (Day 0). Exclusion Criteria: * Clinically significant spine compression fracture, spinal stenosis, or spinal instability. * Clinically significant sacroiliac joint dysfunction, facet joint pain, or those who are suspected. * Modic change type III assessed by X-ray and MRI * History of spine surgery * Neurologic disorders. * Any other systemic disease which can influence spine such as rheumatoid arthritis, ankylosing spondylitis, or autoimmune disease. * Participation in other clinical trials with intradiscal injection (eg, Phase 1/2a YH14618-201 trial, or Cell therapy, etc.)